PATENT CLAIM ANALYSIS

Application Number: 15769065
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["544", "242000"]

Abstract:
The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl) amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy]quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.

Claim (Index 20):
A method of preventing or treating or lessening the severity of a proliferative disorder in a patient, comprising administering to the patient a therapeutically effective amount of the compound of  claim 1 ; wherein the proliferative disorder is metastatic cancer, skin cancer, colon cancer, stomach cancer, bladder cancer, breast cancer, renal cancer, liver cancer, lung cancer, thyroid cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, central nervous system cancer, malignant glioma, bone marrow hyperplasia, atherosclerosis or lung fibrosis.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 91.0
- Lexical Diversity: 1.71154
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13003216', '15314938', '15778220', '14896992', '15539147']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7550044254808982
- 35 USC 102 Novelty (BERT): 0.4835919516264392
- Combined Prediction Score: 0.7278631780954523
- Mean Citation Score: 210.23572400000003
- Max Citation Score: 218.16515
- Similarity Product: 163.6345775127649

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test